VJOncology is committed to improving our service to you

ASCO 2019 | FIERCE-22 trial: vofatamab with pembrolizumab for urothelial carcinoma

VJOncology is committed to improving our service to you

Arlene Siefker-Radtke

Here, Arlene Siefker-Radtke, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, provides an updates of the FIERCE-22 trial (NCT03123055) looking vofatamab with pembrolizumab for urothelial carcinoma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter